Nyxoah S.A (NYXH) | Stock Overview & Key Data
Nyxoah S.A. | Mid-cap | Healthcare
Nyxoah S.A. | Mid-cap | Healthcare
Nyxoah S.A Performance Comparison
Stock Range
Today's Range
Low: €3.93
High: €4.05
on September 18, 2025
52 Week Range
Low: €3.84
High: €10.90
on September 17, 2025
on January 20, 2025
All-Time High: €30.00 on July 12, 2021
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€168.7M
EPS
-2.12
P/E Ratio (TTM)
-2.21
Forward P/E
-2.42
P/B Ratio
2.14
PEG Ratio
-0.08
Div. Yield
N/A
ROE
-79.77%
Beta
0.595
Debt to Equity
30.52
Financial Highlights
Profitability
Gross Margin
63.43%
Operating Margin
-1,481.34%
Profit Margin
65.67%
Returns and Earnings
Return on Assets (TTM)
-34.84%
Return on Equity (TTM)
-79.77%
EBITDA
€-72.9M
Net Income (TTM)
€-77.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€0.13
Quarterly Revenue Growth (YoY)
73.80%
Quarterly Earnings Growth (YoY)
73.80%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Nyxoah S.A NYXH | 168.65M Mid-cap | -15.98% | -27.16% | -41.39% | -58.25% | -52.91% | -46.85% | -38.91% | -79.23% |
| Argenx SE ARGX | 39.22B Large-cap | -5.56% | 7.85% | 30.80% | 9.45% | 1.24% | 28.30% | 73.61% | 195.04% |
| UCB S.A UCB | 39.10B Large-cap | -3.00% | 4.12% | 31.16% | 11.75% | 6.35% | 25.08% | 193.06% | 108.12% |
| Fagron NV FAGR | 1.46B Large-cap | -6.22% | -5.77% | -10.50% | 2.62% | 16.95% | 4.93% | 54.82% | -8.07% |
| Ion Beam IBAB | 333.57M Mid-cap | -5.48% | -5.32% | -5.48% | -14.29% | -19.06% | -18.34% | -13.75% | 4.94% |
| Onward Medical N.V ONWD | 245.24M Mid-cap | 0.19% | 24.15% | 16.29% | 9.83% | -3.75% | 5.11% | -16.42% | -59.65% |
Ownership & Short Interest
Insider Ownership
41.73%
Institutional Ownership
22.79%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
71K
Average 90-Day Volume
104K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is NYXH's 52-week high and low?
- In the last 52 weeks, Nyxoah S.A reached a high of €10.90 (on January 20, 2025) and a low of €3.84 (on September 17, 2025).
- What is the market cap and P/E ratio for NYXH?
- Curious about Nyxoah S.A's size and valuation? Its market capitalization stands at 168.65M. When it comes to valuation, the P/E ratio (trailing twelve months) is -2.21, and the forward P/E (looking ahead) is -2.42.
- Does NYXH pay dividends? If so, what's the yield?
- As for dividends, Nyxoah S.A isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Nyxoah S.A's main competitors or similar companies to consider before investing?
When looking at Nyxoah S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX39.22B Healthcare Biotechnology 28.30% 73.61% UCB S.A
UCB39.10B Healthcare Biotechnology 25.08% 193.06% Fagron NV
FAGR1.46B Healthcare Drug Manufacturers - Specialty & Generic 4.93% 54.82% Ion Beam
IBAB333.57M Healthcare Medical Devices -18.34% -13.75% Onward Medical N.V
ONWD245.24M Healthcare Biotechnology 5.11% -16.42% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Nyxoah S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of Nyxoah S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -79.77%, the Debt to Equity ratio from the most recent quarter is 30.52, and its Gross Profit Margin stands at 63.43%.
- What is the recent revenue and earnings growth for NYXH?
- Looking at Nyxoah S.A's growth, its revenue over the trailing twelve months (TTM) was €5M. Compared to the same quarter last year (YoY), quarterly revenue grew by 73.80%, and quarterly earnings saw a YoY growth of 73.80%.
- How much of NYXH stock is held by insiders and institutions?
- Wondering who owns Nyxoah S.A stock? Company insiders (like executives and directors) hold about 41.73% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 22.79%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.